110 related articles for article (PubMed ID: 20356698)
41. Phenotypic characterization of three clinical isolates of Burkholderia pseudomallei in Ceará, Brazil.
Virginio CG; Teixeira MF; Frota CC; Café VS; Rocha MF; Sidrim JJ
Mem Inst Oswaldo Cruz; 2006 Feb; 101(1):95-7. PubMed ID: 16699716
[TBL] [Abstract][Full Text] [Related]
42. Time-kill curves as a tool for targeting ceftazidime serum concentration during continuous infusion for treatment of septicaemic melioidosis.
Soontornpas C; Saraya S; Chulasiri M; Chindavijak B; Mootsikapun P
Int J Antimicrob Agents; 2005 Nov; 26(5):403-7. PubMed ID: 16216470
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of the Etest for studying tigecycline susceptibility of non-pigmented rapidly growing mycobacteria.
Martín-de-Hijas NZ; Fernández-Roblas R; Fernandez-Martínez AI; Gadea I; Esteban J
Int J Antimicrob Agents; 2008 Oct; 32(4):366-7. PubMed ID: 18572391
[No Abstract] [Full Text] [Related]
44. [Identification of the causative agents of glanders and melioidosis by polymerase chain reaction].
Tkachenko GA; Antonov VA; Zamaraev VS; Iliukhin VI
Mol Gen Mikrobiol Virusol; 2003; (3):18-22. PubMed ID: 12966921
[TBL] [Abstract][Full Text] [Related]
45. Burkholderia pseudomallei: abscess in an unusual site.
Kiertiburanakul S; Sungkanuparph S; Kositchiwat S; Vorachit M
J Postgrad Med; 2002; 48(2):124-6. PubMed ID: 12215696
[TBL] [Abstract][Full Text] [Related]
46. Clinical Manifestations, Antimicrobial Drug Susceptibility Patterns, and Outcomes in Melioidosis Cases, India.
Koshy M; Jagannati M; Ralph R; Victor P; David T; Sathyendra S; Veeraraghavan B; Varghese GM
Emerg Infect Dis; 2019 Feb; 25(2):316-320. PubMed ID: 30666953
[TBL] [Abstract][Full Text] [Related]
47. Tigecycline.
Pankey GA
J Antimicrob Chemother; 2005 Sep; 56(3):470-80. PubMed ID: 16040625
[TBL] [Abstract][Full Text] [Related]
48. Comparison of the Etest and broth microdilution method for tigecycline susceptibility testing against clinical isolates of Acinetobacter baumannii from Taiwan.
Liu JW; Jang TN; Cheng YJ; Hsu GJ; Sun W; Lu CT; Hsueh PR;
Int J Antimicrob Agents; 2010 Feb; 35(2):201-2. PubMed ID: 19892530
[No Abstract] [Full Text] [Related]
49. Reduced susceptibility of multidrug-resistant Acinetobacter baumannii to tigecycline in combination with 1-(1-naphthylmethyl)-piperazine is not a pH-dependent phenomenon.
Wareham DW; Gordon NC; Casals JB; Bean DC
J Antimicrob Chemother; 2009 May; 63(5):1075-6. PubMed ID: 19279048
[No Abstract] [Full Text] [Related]
50. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.
Scheetz MH; Qi C; Warren JR; Postelnick MJ; Zembower T; Obias A; Noskin GA
Antimicrob Agents Chemother; 2007 May; 51(5):1621-6. PubMed ID: 17307973
[TBL] [Abstract][Full Text] [Related]
51. Melioidosis of the spleen diagnosed by 16S rDNA amplification and sequencing.
Chlebicki MP; Tan BH; Koh TH
Scand J Infect Dis; 2005; 37(6-7):517-20. PubMed ID: 16012017
[TBL] [Abstract][Full Text] [Related]
52. Pediatric melioidosis in Pahang, Malaysia.
How HS; Ng KH; Yeo HB; Tee HP; Shah A
J Microbiol Immunol Infect; 2005 Oct; 38(5):314-9. PubMed ID: 16211138
[TBL] [Abstract][Full Text] [Related]
53. Severe community-acquired pneumonia and sepsis caused by Burkholderia pseudomallei associated with flooding in Puerto Rico.
Christenson B; Fuxench Z; Morales JA; Suárez-Villamil RA; Souchet LM
Bol Asoc Med P R; 2003; 95(6):17-20. PubMed ID: 15449787
[TBL] [Abstract][Full Text] [Related]
54. Evaluating New Compounds to Treat
Ross BN; Myers JN; Muruato LA; Tapia D; Torres AG
Front Cell Infect Microbiol; 2018; 8():210. PubMed ID: 30013953
[No Abstract] [Full Text] [Related]
55. Synergistic interaction between phenothiazines and antimicrobial agents against Burkholderia pseudomallei.
Chan YY; Ong YM; Chua KL
Antimicrob Agents Chemother; 2007 Feb; 51(2):623-30. PubMed ID: 17145801
[TBL] [Abstract][Full Text] [Related]
56. A Burkholderia pseudomallei Infection Imported from Eritrea to Israel.
Almog Y; Yagel Y; Geffen Y; Yagupsky P
Am J Trop Med Hyg; 2016 Nov; 95(5):997-998. PubMed ID: 27573625
[TBL] [Abstract][Full Text] [Related]
57. Antimicrobial Susceptibility of Western Hemisphere Isolates of
Bugrysheva JV; Lascols C; McLaughlin HP; Gee JE; Elrod MG; Sue D
Microb Drug Resist; 2021 Sep; 27(9):1176-1185. PubMed ID: 33570476
[TBL] [Abstract][Full Text] [Related]
58. In vitro activity of tebipenem against Burkholderia pseudomallei.
Seenama C; Tiengrim S; Thamlikitkul V
Int J Antimicrob Agents; 2013 Oct; 42(4):375. PubMed ID: 23978354
[No Abstract] [Full Text] [Related]
59. Aminoglycoside and macrolide resistance in Burkholderia pseudomallei.
Simpson AJ; White NJ; Wuthiekanun V
Antimicrob Agents Chemother; 1999 Sep; 43(9):2332. PubMed ID: 10577350
[No Abstract] [Full Text] [Related]
60. The effect of methanolic extract of Tamarindus indica Linn. on the growth of clinical isolates of Burkholderia pseudomallei.
Muthu SE; Nandakumar S; Rao UA
Indian J Med Res; 2005 Dec; 122(6):525-8. PubMed ID: 16518004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
